Soligenix (SNGX) Non-Current Assets (2010 - 2026)
Soligenix's (SNGX) quarterly Non-Current Assets came in at $357392.0 in Q1 2026, up 239.15% YoY from $105378.0 in Q1 2025, and down 7.53% on a QoQ basis from $386514.0 in Q4 2025.
Soligenix (SNGX) Non-Current Assets (2010 - 2026) Analysis & Trends
Soligenix (SNGX) has 17 years of Non-Current Assets data on file, last reported at $357392.0 in Q1 2026.
- Quarterly Non-Current Assets rose 239.15% year-over-year to $357392.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 million (up 159.47% YoY) and the FY2025 annual result came in at $386514.0, up 180.38% from the prior year.
- Non-Current Assets eased to $357392.0 in Q1 2026, from $386514.0 in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $486831.0 in Q2 2022 to a low of $105378.0 in Q1 2025.
- A 5-year average of $316262.5 and a median of $354947.0 in 2023 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2025 — Non-Current Assets sank 56.09% — and 2026, when it surged 239.15%.
- Tracing SNGX's Non-Current Assets over 5 years: stood at $426565.0 in 2022, then plunged by 32.01% to $290006.0 in 2023, then sank by 52.47% to $137853.0 in 2024, then soared by 180.38% to $386514.0 in 2025, then dropped by 7.53% to $357392.0 in 2026.
- The last three Non-Current Assets figures came in at $357392.0 (Q1 2026), $386514.0 (Q4 2025), and $413004.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.00 Bn | 132.14 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.24 Bn | 60.06 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 62.41 Bn | 57.27 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.25 Bn | 37.15 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.18 Bn | 27.88 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.93 Bn | 10.54 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.28 Bn | 26.44 Bn | - | 18.06 Bn |
| 10 | Soligenix | 6.06 Mn | 6.06 Mn | - | 327,684.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 327,684.00 |
| Mar 31, 2026 | 357,392.00 |
| Dec 31, 2025 | 386,514.00 |
| Sep 30, 2025 | 413,004.00 |
| Jun 30, 2025 | 440,195.00 |
| Mar 31, 2025 | 105,378.00 |
| Dec 31, 2024 | 137,853.00 |
| Sep 30, 2024 | 170,087.00 |
| Jun 30, 2024 | 202,207.00 |
| Mar 31, 2024 | 239,998.00 |
| Dec 31, 2023 | 290,006.00 |
| Sep 30, 2023 | 330,954.00 |
| Jun 30, 2023 | 354,947.00 |
| Mar 31, 2023 | 379,870.00 |
| Dec 31, 2022 | 426,565.00 |
| Sep 30, 2022 | 454,262.00 |
| Jun 30, 2022 | 486,831.00 |
| Mar 31, 2022 | 200,400.00 |
| Dec 31, 2021 | 300,406.00 |
| Sep 30, 2021 | 273,260.00 |